Can Surging InP Demand Strengthen AXT's Long-Term Growth Potential?

AXT reported record Q2 2026 revenue of $47.6 million, including record InP revenue of $30.7 million, and a 44.9% GAAP gross margin; its InP backlog exceeds $100 million. Capacity is being doubled in 2026, with another expansion planned for 2027, and customer commitments include $25.4 million of Casela purchases in 2027 and a six-year Lumentum reservation backed by an initial $43.5 million deposit. China export-permit requirements could delay shipments and revenue; AXTI is up 425.2% year to date and trades at 14.19X forward sales versus a 5.25X industry average.

Analysis

AXTI’s risk/reward has shifted from demand discovery to execution: the market is already capitalizing substantial future growth, leaving little room for capacity ramps, export approvals, or customer qualification to slip. The key second-order risk is that a large backlog is not equivalent to near-term revenue or cash generation; permit delays can strand output and working capital, while customer prepayments mitigate funding pressure but also raise delivery obligations. The 2027 expansion could support growth if utilization stays high, but it increases the danger of oversupply if optical demand or customer timing disappoints.

Over the next 1–3 months, watch InP shipments versus backlog, export-permit turnaround, and whether margin gains persist as volumes rise. Over 6–18 months, the test is whether capacity additions convert to sustained free-cash-flow generation rather than merely higher reported sales. Lumentum has a more balanced exposure: it competes in InP while also securing substrate supply and selling downstream optical products. That makes it a potential relative-value hedge, not a pure short beneficiary. The contrarian point is that AI optics demand may be real while AXTI equity upside is still limited by its already exceptional rerating. A permit normalization and clean capacity ramp would falsify the cautious near-term view; repeated shipment deferrals or margin deterioration would strengthen it.

Key Decisions for Investors

• Avoid chasing AXTI after its exceptional rerating; consider a small, defined-risk underweight rather than an outright large short. The valuation leaves asymmetric downside if execution slips, but short-squeeze risk remains high.
• For a relative-value expression, consider short AXTI against long LITE in modest size: this hedges some optical-demand exposure while favoring the downstream company’s more diversified position. Reassess if Lumentum’s own optical-product ramp weakens or its InP sourcing becomes constrained.
• Treat AXTI’s backlog and customer commitments as conditional visibility, not booked earnings. Before adding, verify permit approvals, shipment conversion, capacity utilization, and operating cash flow in subsequent results.
• Thesis invalidation: AXTI consistently converts backlog into shipments without permit-related slippage, sustains gross-margin improvement through the capacity ramp, and demonstrates cash conversion; in that case, reduce the underweight.